{"Clinical Trial ID": "NCT02005549", "Intervention": ["INTERVENTION 1:", "Bevacizumab+Docetaxel+Capecitabine", "Participants received bevacizumab, 15 mg/kg IV, followed by docetaxel 75 mg/m^2 IV on day 1 and capecitabine 950 mg/m^2 PO BID within 30 minutes of the end of a meal, starting on the evening of day 1 and continuing until the morning of day 15 (following a rest period of 7 days) for a maximum of five cycles of 3 weeks."], "Eligibility": ["Incorporation criteria:", "\u2022 Patients aged 18 to 70;", "Invasive breast cancer proven by histology;", "No previous or current neoplasm except for non-melanoma skin cancer or in situ cervical cancer;", "No distant disease/secondary cancer.", "- Exclusion criteria:", "Pregnant or lactating women;", "Local pre-operative treatment of breast cancer;", "Previous or concomitant systemic anti-tumour treatment;", "A clinically significant heart disease."], "Results": ["Performance measures:", "Percentage of participants with a complete pathological response (pCR)", "PCR was defined as the absence of signs of invasive tumour in the final surgical sample, as determined by the local pathologist. Surgery was performed 2 to 4 weeks after the last chemotherapy cycle.", "Delay: Baseline, 20-24 weeks (final operation, 2 to 4 weeks after last chemotherapy cycle [Week 18])", "Results 1:", "Title of the arm/group: Bevacizumab+Docetaxel+Capecitabine", "The participants received bevacizumab, 15 mg/kg IV, followed by docetaxel 75 mg/m^2 IV on day 1 and capecitabine 950 mg/m^2 PO BID within 30 minutes of the end of a meal, starting on the evening of day 1 and continuing until the morning of day 15 (following a rest period of 7 days) for a maximum of five cycles of 3 weeks.", "Total number of participants analysed: 18", "Type of measurement: Number", "Unit of measure: percentage of participants 22.22 (6.41 to 47.64)"], "Adverse Events": ["Undesirable Events 1:", "Total: 5/18 (27.78%)", "Intestinal perforation value * 1/18 (5.56%)", "* 1/18 (5.56 per cent)", "* 1/18 (5.56 per cent)", "Neutropenic infection * 1/18 (5.56%)", "Contralateral breast cancer * 1/18 (5.56%)", "Menorragia * 1/18 (5.56 per cent)", "Deep venous thrombosis * 2/18 (11.11 %)"]}